Ugeskr Læger 2016;178:V06160406
Pharmacotherapy for obesity
Obesity is a chronic condition, which is why pharmacotherapy can be considered, if lifestyle modification (hypocaloric diet/exercise) does not result in a weight loss of at least 5%. Pharmacotherapy is indicated, if an individual has a BMI > 30 kg/m2 or a BMI > 27 kg/m2 and concomitant disease (e.g. Type 2 diabetes), and can be liraglutide (3 mg) or orlistat (120 mg/60 mg). Choice of treatment must be based on patient preferences and clinical situation, side effects, contraindications and financial considerations. Weight loss of < 5% (about 4-5 kg) after 12 weeks should lead to cessation of the treatment.